Regulus Therapeutics Analysis
| RGLSDelisted Stock | USD 8.16 0.01 0.12% |
Regulus Therapeutics holds a debt-to-equity ratio of 0.169. Regulus Therapeutics' financial risk is the risk to Regulus Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Regulus Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Regulus Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Regulus Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Regulus Therapeutics' stakeholders.
For most companies, including Regulus Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Regulus Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Regulus Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Regulus Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Regulus Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Regulus Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Regulus Therapeutics is said to be less leveraged. If creditors hold a majority of Regulus Therapeutics' assets, the Company is said to be highly leveraged.
Regulus Therapeutics is overvalued with Real Value of 5.57 and Hype Value of 8.16. The main objective of Regulus Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Regulus Therapeutics is worth, separate from its market price. There are two main types of Regulus Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Regulus Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Regulus Therapeutics is usually not traded on Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday. Regulus Stock trading window is adjusted to America/New York timezone.
Regulus |
Regulus Stock Analysis Notes
About 83.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.68. Regulus Therapeutics last dividend was issued on the 4th of October 2018. The entity had 1:10 split on the 29th of June 2022. Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Regulus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Regulus Therapeutics contact Joseph MBA at 858 202 6300 or learn more at https://www.regulusrx.com.Regulus Therapeutics Investment Alerts
| Regulus Therapeutics is not yet fully synchronised with the market data | |
| Regulus Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (46.36 M) with loss before overhead, payroll, taxes, and interest of (36.15 M). | |
| Regulus Therapeutics currently holds about 47.53 M in cash with (41.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.25. | |
| Over 83.0% of the company shares are owned by institutional investors |
Regulus Therapeutics Upcoming and Recent Events
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Regulus Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 564.95 M.Regulus Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regulus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regulus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regulus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Regulus Therapeutics Outstanding Bonds
Regulus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regulus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regulus bonds can be classified according to their maturity, which is the date when Regulus Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US75913MAA71 Corp BondUS75913MAA71 | View | |
| REGIONS FINL P Corp BondUS7591EPAE09 | View | |
| RF 18 12 AUG 28 Corp BondUS7591EPAT77 | View |
Regulus Therapeutics Debt to Cash Allocation
Many companies such as Regulus Therapeutics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Regulus Therapeutics currently holds 274 K in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Regulus Therapeutics has a current ratio of 8.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Regulus Therapeutics' use of debt, we should always consider it together with its cash and equity.Regulus Therapeutics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Regulus Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Regulus Therapeutics, which in turn will lower the firm's financial flexibility.Regulus Therapeutics Corporate Bonds Issued
About Regulus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Regulus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Regulus shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Regulus Therapeutics. By using and applying Regulus Stock analysis, traders can create a robust methodology for identifying Regulus entry and exit points for their positions.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Regulus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Regulus Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Technical Analysis Now
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Regulus Stock
If you are still planning to invest in Regulus Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regulus Therapeutics' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |